Key Takeaways UBER shares reached a 52-week high of $97.12, surging 60.3% YTD and outperforming Lyft and its industry. UBER may acquire Pony AI's U.S. arm, deepening its push into the autonomous vehicle market. UBER posted a $2.25B free cash flow in Q1 and expects up to 35% EBITDA growth in 2Q25.Uber Technologies (UBER) has been experiencing a great run on the bourses lately. Shares of this U.S. ride-hailing giant hit a 52-week high of $97.12 on July 7 and finally closed at $96.68, surging 60.3% year to d ...

Key Takeaways XPEV has launched deliveries of its new G7 SUV just days after its official market debut. The G7 includes XPeng's Turing AI chip with 2,250 TOPS, the highest in any smart EV to date. XPEV aims to sell 100,000 G7s annually, projecting 55,000 units in the second half of 2025.XPeng Inc. (XPEV) has begun delivering its newly launched G7 SUV, just days after its official debut. He Xiaopeng, chairman and CEO of XPeng, personally handed over some of the first vehicles to customers in Shanghai, per ...

Key Takeaways NIKE's Win Now strategy targets growth via sport-led innovation and streamlined product focus. FY25 revenues for NIKE fell 10%, with headwinds from China, digital shifts and elevated inventories. LULU Q1 revenues grew 7% y/y and gross margin rose 60 bps, driven by global expansion and product traction.The dynamic world of athletic apparel is marked by two titans vying for dominance: NIKE Inc. (NKE) , the undisputed global sportswear giant, and lululemon athletica inc. (LULU) , the sleek disr ...

Key Takeaways SCHW reached a 52-week high of $92.65, gaining 23.1% over the past three months. Higher client assets, market volatility and advisory growth are driving top-line expansion. Improved NIM and reduced funding costs support earnings, despite rising operating expenses.Charles Schwab (SCHW) touched a 52-week high of $92.65 during yesterday’s trading session. Over the past three months, the stock has gained 23.1%, underperforming the industry but outperforming the Zacks Finance sector and the S&P 5 ...

NEW YORK, July 8, 2025 /PRNewswire/ -- OneMain Holdings, Inc. (NYSE: OMF), the leader in offering nonprime consumers responsible access to credit, plans to report its second quarter 2025 results before the market opens on Friday, July 25, 2025. The earnings release will be available on OneMain's investor relations website at http://investor.onemainfinancial.com.A conference call to discuss the company's results, outlook and related matters will be held that morning at 9:00 a.m. Eastern. The general public i ...

 Simple Steps to Minimize Damage and Stay Safe During Hurricane SeasonLOS ANGELES, July 8, 2025 /PRNewswire/ -- Hurricane season brings with it a mix of unpredictability and urgency — and while you can't stop a storm, you can absolutely prepare for one. Mercury Insurance is sharing practical, proactive steps homeowners can take to protect their property and loved ones before a hurricane makes landfall.With decades of experience helping policyholders recover from major storms, Mercury understands that prepar ...

LOS ANGELES, July 8, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Reddit, Inc. ("Reddit" or the "Company") (NYSE: RDDT) have opportunity to lead the securities fraud class action lawsuit.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN EDDIT, INC. (RDDT), CLICK HERE BEFORE AUGUST 18, 2025 (THE LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. What Is The Lawsuit About? The complaint filed alleges that, between October 29, 2 ...

MILWAUKEE, July 8, 2025 /PRNewswire/ -- The Ademi Firm is investigating CARGO (NASDAQ: CRGX) for possible breaches of fiduciary duty and other violations of law in its transaction with Concentra Biosciences.Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you.In the transaction, shareholders of CARGO will receive $4.379 in cash per share, plus one non-transferable contingent va ...

Core Viewpoint - The Coca-Cola Company (KO) has experienced modest stock performance with a 1.5% increase over the past three months, reflecting investor caution despite stable fundamentals [1][3]. Financial Performance - In the first quarter of fiscal 2025, Coca-Cola reported a 3% organic revenue growth, driven by strong pricing and product mix, although volume growth was slower in North America due to inflation and cautious consumer behavior [2][8][13]. - The company maintained a conservative full-year outlook, indicating potential macroeconomic headwinds and limited near-term earnings acceleration [2][15]. - The Zacks Consensus Estimate for Coca-Cola's 2025 revenues and EPS implies year-over-year growth of 2.5% and 3.1%, respectively, while estimates for 2026 suggest growth of 5.3% and 8.2% [17][18]. Market Position - Coca-Cola's stock has outperformed the Zacks Beverages – Soft Drinks industry, which declined by 0.3% in the same period, but underperformed the broader Zacks Consumer Staples sector and the S&P 500 [3][4]. - The current share price of $71.01 is 4.5% below its 52-week high of $74.38 and 17.1% above its 52-week low of $60.62 [7]. Competitive Landscape - Coca-Cola's performance is weaker compared to Monster Beverage, which saw a 7.6% increase, but it outperformed PepsiCo and Keurig Dr Pepper, which declined by 7.7% and 2.7%, respectively [4][3]. - Coca-Cola trades at a forward P/E of 22.97X, significantly higher than the industry average of 18.66X, raising concerns about whether its valuation is justified [19][21]. Strategic Initiatives - The company is focusing on digital transformation and innovation, with marketing strategies aimed at deepening consumer engagement, particularly in emerging markets [14][15]. - Coca-Cola's ability to maintain pricing strength and product mix without compromising competitiveness highlights the durability of its brand portfolio [13][15]. Investment Outlook - Despite trading at a premium compared to peers, Coca-Cola offers a mix of steady returns, defensive stability, and long-term growth potential, making it a compelling investment option [23][24]. - The stock's premium valuation reflects strong investor expectations for growth, and any market pullbacks may present strategic entry points for investors [22][24].

Key Takeaways COGT soared after its SUMMIT study met all endpoints in non-advanced systemic mastocytosis. Bezuclastinib showed strong symptom reduction and biomarker response versus placebo. The drug was well-tolerated, and an FDA submission is targeted for the end of 2025.Shares of Cogent Biosciences (COGT) soared 23.4% on Monday after the company reported positive top-line data from a late-stage study of its investigational candidate, bezuclastinib, for treating non-advanced systemic mastocytosis (SM) p ...